CTRI/2023/09/057564
尚未招募
2 期
A randomized placebo control study to evaluate the effect of AYUSH SR as adjunct to usual care for cardiac rehabilitation on biochemical, physical and psychological parameters, in adult patients who underwent Coronary Artery Bypass Graft (CABG) - Nil
Central Council for Research in Ayurvedic Science (CCRAS) Ministry of AYUSH, Government of India0 个研究点目标入组 0 人待定
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- 发起方
- Central Council for Research in Ayurvedic Science (CCRAS) Ministry of AYUSH, Government of India
- 状态
- 尚未招募
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\.Patients admitted for CABG surgery
- •2\.Male or female patient’s between 18\-65 years of age.
- •3\.Subjects who underwent CABG surgery within the last 5 days with a relatively uncomplicated perioperative period
- •4\.Subjects ready to give informed written consent
- •5\.Subjects willing for follow up till 3 months after the intervention.
排除标准
- •1\.Subjects with severe respiratory or cardiac compromise, uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease or active infection.
- •2\. complications during CABG surgery such as prolonged requirement for mechanical ventilation, acute kidney injury, and bleeding requiring transfusion or reoperation etc that may affect the clinical outcome in patients may also be excluded in the trial
- •3\.History or diagnosis of sleep disorder, use of any other medicines with similar effect to that of AYUSH SR or using any other herbal medicines will be excluded.
- •4\.Subjects with history of or current neurological or psychiatric impairment, or cognitive dysfunction that could compromise data collection.
- •5\. Patients with any concurrent hepatic disorder (defined as liver enzymes SGOT/SGPT \>2 times upper normal limit) or Renal Disorders (defined as S.Creatinine \>1\.4mg/dl).
- •6\.Patients with poorly controlled Hypertension ( \>160/100 mm of Hg) \& poorly controlled Diabetes Mellitus (HbA1c \>8\.0%) may be excluded
结局指标
主要结局
未指定
相似试验
进行中（未招募）
2 期
A Study to Understand The Efficacy Of Individualized Homoeopathic Medicines In Cases Of Haemorrhoids- A Randomized Placebo Control TrialHealth Condition 1: K649- Unspecified hemorrhoidsCTRI/2023/09/058050Jawaharlal Nehru Homoeopathic Medical College & Hospital
进行中（未招募）
不适用
Safety and efficacy of tocilizumab in combination with placebo compared with tocilizumab in combination with methotrexate, with possible addition of other disease-modifying antirheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis who are not responding adequately to their current therapy with methotrexateEUCTR2008-001847-20-LVF Hoffmann-La Roche Ltd.470
进行中（未招募）
不适用
Safety and efficacy of tocilizumab in combination with placebo compared with tocilizumab in combination with methotrexate, with possible addition of other disease-modifying antirheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis who are not responding adequately to their current therapy with methotrexateRheumatoid ArthritisMedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2008-001847-20-DEF Hoffmann-La Roche Ltd.470
进行中（未招募）
不适用
Safety and efficacy of tocilizumab in combination with placebo compared with tocilizumab in combination with methotrexate, with possible addition of other disease-modifying antirheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis who are not responding adequately to their current therapy with methotrexateRheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2008-001847-20-DKF Hoffmann-La Roche Ltd.470
进行中（未招募）
不适用
Randomized placebo-controlled study to evaluate the safety and efficacy of adding tocilizumab (TCZ) to methotrexate (MTX) versus switching to TCZ (placebo controlled), with possible addition of other disease-modifying anti-rheumatic drugs (DMARDs), in patients with active rheumatoid arthritis who have inadequately responded to prior MTX treatment. - ACT-RAYRheumatoid ArthritisEUCTR2008-001847-20-NLF Hoffmann-La Roche Ltd470